Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for treating chronic kidney region fibrosis and its preparation method

A technology of renal interstitial fibrosis and composition, which is applied in the field of pharmaceutical composition for the treatment of chronic renal interstitial fibrosis and its preparation, and can solve problems such as unclear pathogenesis, end-stage renal failure, and no treatment methods, etc. Achieve the effect of reversing or alleviating renal interstitial fibrosis and improving renal function

Inactive Publication Date: 2009-10-07
杨彦芳
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the pathogenesis of AAN is still not very clear, and there is no good treatment.
In recent years, reports on chronic aristolochic acid nephropathy (chronica aristolochic acid nephropathy, CAAN) caused by Guan Mutong and other traditional Chinese medicines containing aristolochic acid have also been widely reported. Interstitial fibrosis is the main feature. Not only the disease develops rapidly, but also it is very harmful. It can often cause irreversible end-stage renal failure. So far there is no mature treatment plan

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating chronic kidney region fibrosis and its preparation method
  • Medicinal composition for treating chronic kidney region fibrosis and its preparation method
  • Medicinal composition for treating chronic kidney region fibrosis and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0036] Experimental Example 1 Yishen Ruanjian Powder Containing Serum Antagonizes the Effect of Aristolochic Acid on Human Renal Interstitial Fibroblasts

[0037] Male SD rats, 2 months old, with a body weight of 270-290g, fasted for 16 hours, without anesthesia, were gavaged with Yishenruanjian powder water decoction (11ml / kg body weight for each gavage, which is equivalent to 60kg 10 times the body weight of a person), blood was collected from the inner canthus vein of rats at 1h after the single gavage and 0.5h, 1h and 1.5h after the second gavage (interval 2h) respectively (6 rats were taken at each time point ), the serum was collected after centrifugation, and the sera of 6 rats were mixed, sterilized by filtration, and inactivated at 56° C. for 30 min. This was the drug-containing serum for the experiment. Rat normal serum was obtained in the same way. High performance liquid chromatography (high performance liquid chromatography, HPLC) was used to determine the conten...

experiment example 2

[0051] Experimental Example 2 Yishen Ruanjian Powder Containing Serum Antagonizes the Effect of Aristolochic Acid on Human Proximal Renal Tubular Epithelial Cells

[0052] (1) Detection of rat serum and AA-Na on HKC cell proliferation and toxicity

[0053] The results of the LDH release experiment showed that when the drug-containing serum content of rats was 5% and 10%, there was no obvious toxic effect on HKC cells (P>0.05), while the drug-containing serum of rats had a killing effect on HKC when the content was 20% (P -1 No obvious toxic effect on HKC (P>0.05), while 80mg·L -1At this time, AA-Na can kill HKC (P-1 . For this reason, add AA-Na40mg·L to 10% rat serum containing medicine -1 The cytotoxicity test was carried out again, and there was no significant difference in the release rate of LDH compared with the control group (P>0.05) (Table 1). The above results indicated that the co-incubation of AA-Na with the content of this experiment and the drug-containing serum...

experiment example 3

[0069] Experimental Example 3 Protective Effect of Yishen Ruanjian Powder on Renal Interstitial Fibrosis in Chronic Aristolochic Acid Nephropathy Rat Model

[0070] Eighteen male SD rats were divided into 3 groups with 6 rats in each group. Control group: intragastric administration with tap water every morning; model group: intragastric administration with Guan Mutong extract aqueous solution in the morning, the method was the same as that in the literature; Oral gavage in the afternoon of the first day; a total of 16 weeks.

[0071] (1) Comparison of body weight of rats in each group at different time points

[0072] Before the experiment, there was no significant difference in the body weight of the rats in each group (data omitted), and the body weight of the rats in the model group and the Chinese medicine group were significantly lower than that of the control group after administration; the rats in the Chinese medicine group and the model group had no significant diffe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A Chinese medicine for treating chronic renal interstitial fibrosis and chronic renal insufficiency is prepared from 10 Chinese-medicinal materials including red sage root, astragalus root, Chinese angelica root, notoginseng, etc. Its preparing process is also disclosed.

Description

field of invention [0001] The invention relates to a pharmaceutical composition, a preparation method thereof, and a new pharmaceutical application, in particular to a pharmaceutical composition for treating chronic renal interstitial fibrosis, a preparation method thereof, and a new pharmaceutical application. Background technique [0002] Aristolochic acid nephropathy (aristolochic acid nephropathy, AAN) caused by Chinese herbal medicines containing aristolochic acid (AA) has been confirmed and has been paid more and more attention. However, the pathogenesis of AAN is still not very clear, and there is no good treatment. In recent years, reports on chronic aristolochic acid nephropathy (chronica aristolochic acid nephropathy, CAAN) caused by Guan Mutong and other traditional Chinese medicines containing aristolochic acid have also been widely reported. Interstitial fibrosis is the main feature. It not only develops rapidly, but also is very harmful. It can often cause irr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/906A61K36/708A61K36/53A61K36/481A61K36/258A61K36/232A61K36/21A61K36/068A61K35/56A61P13/12A61K35/586
Inventor 杨彦芳
Owner 杨彦芳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com